Modern 2DR in Belgium & beyond: what have we learned?
Expired
This course is expired
DTG-based 2 drug-regimens (2DR) are currently amongst the standard of care for treating patients living with HIV. Real-world treatment adherence and strict inclusion criteria used during RCTs can lead to several patient groups being underrepresented. Therefore, real-world data on DTG-based 2DRs are highly needed to be able to evaluate virologic and safety outcomes in these underrepresented patient groups.
In this webinar, Dr. Nasreddine highlighted the outcomes of the BREACH DTG-based 2DR cohort, a retrospective, observational, multicenter study (n=10).
Subsequently Prof. De Wit, Chair of the Belgian HIV Research Consortium BREACH, gave his clinical implications of these cohort data.
Finally, Dr. De Scheerder provided a comprehensive overview of the real-world DTG/3TC data that are currently available beyond Belgium.
PROGRAMME:
Instructor :
Dr. Rakan NASREDDINE
Instructor :
Prof. Stéphane DE WIT
Instructor :
Dr. Marie-Angélique DE SCHEERDER
Instructors
Dr. Rakan NASREDDINE
Infectious disease specialist & HIV researcher - Saint-Pierre University Hospital
Prof. Stéphane DE WIT
Saint-Pierre University Hospital | Chair of BREACH
Dr. Marie-Angélique DE SCHEERDER
Infectious disease specialist UZ gent | Ghent University
Please report adverse events to the Belgian Centre for Pharmacovigilance for medicines for Human use of the Federal Agency for Medicines and Health Products [email protected] or via the ‘yellow card’ available on www.fagg-afmps.be or to ViiV HealthCare srl/bv 010/ 85 65 00.
Click here for SmPC of DOVATO and JULUCA.
ER/VU/RE: ViiV Healthcare srl/bv Site Apollo Avenue Pascal, 2-4-6 1300 Wavre Belgium
DTG-based 2 drug-regimens (2DR) are currently amongst the standard of care for treating patients living with HIV. Real-world treatment adherence and strict inclusion criteria used during RCTs can lead to several patient groups being underrepresented. Therefore, real-world data on DTG-based 2DRs are highly needed to be able to evaluate virologic and safety outcomes in these underrepresented patient groups.
In this webinar, Dr. Nasreddine highlighted the outcomes of the BREACH DTG-based 2DR cohort, a retrospective, observational, multicenter study (n=10).
Subsequently Prof. De Wit, Chair of the Belgian HIV Research Consortium BREACH, gave his clinical implications of these cohort data.
Finally, Dr. De Scheerder provided a comprehensive overview of the real-world DTG/3TC data that are currently available beyond Belgium.
PROGRAMME:
Instructor :
Dr. Rakan NASREDDINE
Instructor :
Prof. Stéphane DE WIT